Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30
Revenue grew 19% to ₹9,041 mn, net profit rose 9% to ₹664 mn. Results were widely anticipated with no material surprises.
— 3 earlier stories on Windlas Biotech Ltd. →Mkt cap₹1,773 cr
P/E26.67×
ROE12.06%
Debt / eq.0.05
Div yld0.73%
9% Net profit growth to ₹664 mn
What's new
- FY26 revenue up 19% YoY to ₹9,041 mn
- Net profit rose 9% YoY to ₹664 mn
- Dividend hiked from ₹5 to ₹6.30 per share
Why this matters
Steady operational performance but fully expected after prior guidance and buyback completion. No new tradeable insights for the micro-cap pharma stock.
What we're watching
- Any change in growth trajectory in FY27
- Sustainability of margin trends
The full read
Windlas Biotech's audited FY26 results confirm the trajectory already implied by its buyback and prior commentary. Revenue hit ₹9,041 million, up 19%, and net profit rose 9% to ₹664 million. The dividend increase to ₹6.30 per share (126% face value) is modest but welcome. The numbers are clean but routine — no surprises, no guidance deviation. For a micro-cap pharma that has already communicated its outlook, this annual filing offers nothing to alter the consensus view.
Mentioned: ₹9,041 mn revenue · ₹664 mn profit · ₹6.30 dividend
Company snapshot
Windlas Biotech Ltd.
Pharmaceuticals
₹1,650 cr
P/E 24.73×
Latest quarter · Mar 2026
Sales₹238 cr
Net profit₹16 cr
Op. margin+10.6%
EPS₹7.58
Strength & growth
Debt / equity0.05×
Current ratio2.11×
Story so far
All notes on WINDLAS →- 21 May 2026 · 4:34 PM IST Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30
- 51d ago Windlas Biotech misses Plant 6 timeline as regulatory hit cuts revenue
- 52d ago Windlas Biotech’s ₹904 Cr revenue: record, but already priced in.
- 52d ago Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26